The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a huge mover today! About 2.15M shares traded hands. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 17.02% since April 14, 2016 and is uptrending. It has outperformed by 12.33% the S&P500.
The move comes after 7 months negative chart setup for the $1.26 billion company. It was reported on Nov, 16 by Barchart.com. We have $8.08 PT which if reached, will make NASDAQ:FOLD worth $100.80M less.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage
Out of 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Amicus Therapeutics has been the topic of 11 analyst reports since August 18, 2015 according to StockzIntelligence Inc. As per Wednesday, May 18, the company rating was initiated by Bank of America. The firm earned “Outperform” rating on Monday, October 5 by Leerink Swann. Chardan Capital Markets upgraded it to “Buy” rating and $8 target price in Monday, October 5 report. The company was maintained on Tuesday, September 1 by Cowen & Co. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Buy” rating by Leerink Swann on Monday, August 31. On Tuesday, September 8 the stock rating was maintained by JP Morgan with “Overweight”. Chardan Capital Markets downgraded it to “Neutral” rating and $17 target price in Wednesday, September 16 report. The firm has “Neutral” rating given on Thursday, April 14 by Robert W. Baird. Zacks downgraded Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, August 18 to “Buy” rating. The rating was upgraded by Janney Capital on Tuesday, March 8 to “Buy”.
According to Zacks Investment Research, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.”
Insitutional Activity: The institutional sentiment increased to 1.64 in Q2 2016. Its up 0.71, from 0.93 in 2016Q1. The ratio increased, as 20 funds sold all Amicus Therapeutics, Inc. shares owned while 25 reduced positions. 22 funds bought stakes while 52 increased positions. They now own 136.20 million shares or 2.45% more from 132.95 million shares in 2016Q1.
Blackrock holds 0% or 26,443 shares in its portfolio. Stevens Cap Limited Partnership holds 16,824 shares or 0% of its portfolio. Emerald Advisers Inc Pa last reported 1.06 million shares in the company. Geode Management last reported 0% of its portfolio in the stock. Cqs Cayman Limited Partnership holds 0.67% or 1.39 million shares in its portfolio. Numeric Invsts Limited Liability Company, a Massachusetts-based fund reported 75,900 shares. California Public Employees Retirement System has 276,800 shares for 0% of their US portfolio. California State Teachers Retirement Sys reported 267,038 shares or 0% of all its holdings. The California-based Nicholas Inv Ptnrs Lp has invested 0.12% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Rock Springs Capital L P holds 680,000 shares or 0.27% of its portfolio. The New Jersey-based Blackrock Inv Mgmt Ltd has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Perceptive Advsrs Limited Liability Com has 15.24 million shares for 5.77% of their US portfolio. Teacher Retirement Of Texas reported 15,808 shares or 0% of all its holdings. Trexquant Inv Ltd Partnership, a Connecticut-based fund reported 88,486 shares. Alpinvest Ptnrs Bv accumulated 0.68% or 63,203 shares.
Insider Transactions: Since June 2, 2016, the stock had 2 insider purchases, and 9 selling transactions for $8.06 million net activity. $73,206 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) was sold by Barth Jay on Thursday, August 4. Shares for $7.49 million were sold by PERCEPTIVE ADVISORS LLC. Another trade for 25,000 shares valued at $181,250 was made by Do Hung on Monday, October 3. The insider Rosenberg Ellen bought $115,050. 66,300 shares were bought by Redmile Group – LLC, worth $477,360 on Friday, June 3. Shares for $164,075 were sold by Baird William D III. 8,546 shares were sold by Quimi Daphne, worth $68,368.
More news for Amicus Therapeutics, Inc. (NASDAQ:FOLD) were recently published by: Fool.com, which released: “Here’s Why Amicus Therapeutics, Inc. Soared As Much As 20% Despite an Earnings …” on November 07, 2016. Seekingalpha.com‘s article titled: “Solid Progress At Amicus Therapeutics” and published on November 15, 2016 is yet another important article.
FOLD Company Profile
Amicus Therapeutics, Inc., incorporated on February 4, 2002, is a biopharmaceutical company. The Firm is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. The Company’s lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). The Firm has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. The Firm is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa (EB). It has also initiated a clinical study in patients with Pompe disease, another LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with a pharmacological chaperone, AT2221, to improve activity and stability.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.